Comparing Screening Methods for Detection of Early-Stage Gastric Cancer in People with a CHD1 Genetic Mutation identifier:
NCT04535414 (

Gastric cancer screening study for people with a CHD1 inherited mutation

Study Contact Information:

For additional information, please contact:

Jamie Kirkpatrick, R.N. by phone: 240-760-7533 or email: [email protected]

Principal Investigator: Jeremy L. Davis, M.D. by phone: 240-858-3731 or email: [email protected]

About the Study

This study will compare a new technique of screening for a type of inherited gastric cancer known as diffuse hereditary gastric cancer (DHGC) to see if it can identify cancer better than the current recommended screening.  Participants will be assigned by chance to one of two groups to receive screening by the current screening technique, called the Cambridge method, or the new screening technique, called the Bethesda protocol.

What the Study Involves

Participants will be assigned by chance to one of two groups.

Participants in both groups will:

Some participants may have a second endoscopy 6-18 months after their first endoscopy.

Participants in Group 1 will have 88 pieces of tissue taken from 6 areas of their stomach during the endoscopy.

Participants in Group 2 will have 30 pieces of tissue taken from their stomach during the endoscopy. This group will also be injected with a contrast dye after which a microscope will be inserted, and more samples will be taken.

Study Site


National Institutes of Health Clinical Center
Contact National Cancer Institute Referral Office at 888-624-1937

This Study is Open To:

People, 18 years or older, who:

This Study is Not Open To:

This study is not open to people who:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.